Bristol-Myers Squibb (BMY) Faces Mixed Analyst Sentiment Despite Strong Momentum in Healthcare Industry

Bristol-Myers Squibb Company (NYSE:BMY) is included successful our database of the best stocks to bargain for fiscal stability.

Bristol-Myers Squibb Company (NYSE:BMY) is facing mixed expert sentiment, with astir 60% of covering analysts maintaining mixed ratings connected the stock. At the aforesaid time, the statement terms people of $63 implies 10% upside.

The caller expert update came from HSBC, successful which analysts emphasized the healthcare sector’s greater resilience comparative to the broader marketplace amid heightened macro uncertainty tied to rising geopolitical risks. Furthermore, the firm’s analysts noted constricted interaction from AI disruption connected healthcare stocks.

Looking ahead, the steadfast remains assured successful Bristol-Myers Squibb Company’s (NYSE:BMY) outlook arsenic it expects the sector’s resilience to play a important relation successful driving the stock’s outperformance successful the coming quarter.

Accordingly, HSBC boosted its terms people connected the banal from $53 to $60. As of March 17, 2026, the steadfast maintains a “Hold” standing connected Bristol-Myers Squibb Company (NYSE:BMY).

The expert update follows the company’s affirmative late-stage proceedings results for its experimental oral cause mezigdomide successful operation with carfilzomib and dexamethasone for relapsed aggregate myeloma. According to the property merchandise dated March 9, 2026, mezigdomide achieved a important betterment successful diligent endurance compared to the modular regimen. Furthermore, it showed nary accrued hazard of illness worsening and was accordant with its established information profile.

Commenting connected the results, analysts astatine RBC Capital described the information arsenic an incremental positive, with the American Cancer Society projecting astir 36,000 caller U.S. aggregate myeloma cases successful 2026, which reflects the therapy’s marketplace potential.

Bristol-Myers Squibb Company (NYSE:BMY) engages successful the improvement and selling of biopharmaceuticals, including tiny molecules, biologics, and CAR-T therapies. The company’s absorption remains connected discovering innovative treatments for oncology, hematology, and different specialty illness areas globally.

While we admit the imaginable of BMY arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 33 Stocks That Should Double successful 3 Years and 15 Stocks That Will Make You Rich successful 10 Years. 

Disclosure: None. Follow Insider Monkey connected Google News.